Fidia Farmaceutici has now a subsidiary in the Middle East

Fidia Farmaceutici has established a wholly owned subsidiary in Middle East, further enhancing its presence in growing markets.

Continuing its International growth, Fidia farmaceutici, a world leader in hyaluronic acid R&D and manufacturing, announces the opening of a wholly owned subsidiary in the United Arab Emirates. A hub for its operations in the Middle East and North Africa (MENA), Fidia’s 6th subsidiary will be based in Dubai.

The Dubai subsidiary will also provide field support to Fidia farmaceutici’s customers and distributors in the region more thoroughly and effectively, to ensure they receive the highest quality service.

Fidia Pharma Middle East was formally inaugurated on December 1st, 2015 and employs highly professional and dedicated people, with a diversified product portfolio focusing on hyaluronic acid, with specialization in intra-articular Joint Care, Wound Care and Aesthetic Medicine.

The completion of this project further demonstrates Fidia’s transition into a truly global business, and strategic investment into key emerging markets, such as the Middle East.


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine